Global Type 2 Diabetes Market Set to Almost Double to $58.7 Billion
The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%, according to research and consulting firm GlobalData.
The company’s latest report, PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025, states that this growth, which will occur across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, China, and India, will primarily be attributable to a dramatic increase in the diagnosis and prevalence of the disease, and the fact that the rise in type 2 diabetes-related comorbidities has fueled a more aggressive approach in treatment and the use of multiple-drug therapies.
Jesus Cuaron, PhD, PPM, GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, explains “Increases in disease incidences will result from increased life expectancy and lifestyle changes, such as dietary changes and a reduction in exercise. Indeed, the US will be impacted the most by such changes, increasing its global market share from 58% to 66% during the forecast period.”
Due to the increasing prevalence and progressive nature of type 2 diabetes, there are considerably high unmet needs within the indication. Overall, these unmet needs are interrelated and include improved durability of treatment, a better balance of efficacy of glycemic control with cardiovascular safety, hypoglycemia avoidance, and tolerability and ease of compliance.
Cuaron continues “Currently, all available treatments for type 2 diabetes are initially effective and reduce complication rates. The need for drugs that are able to maintain glycemic control in the long-term, however, represents a significant growth opportunity for new patent-protected products. Molecules in the earlier stages of development – Phase II or earlier – employ various novel mechanisms of action. Early stage novel drug classes include those such as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors and glucokinase activators.”
GlobalData believes that in order to address the biggest unmet need in type 2 diabetes, new drugs must address the problem of insulin resistance, as this is the root of the disease. New products must address insulin resistance while offering a strong safety profile and not causing weight gain.
This report provides analysis of the type 2 diabetes treatment space across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, China, and India, including annualized market data from 2015 and forecast to 2025. It was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries. For more information, please contact our Press Office on +44 (0)161 359 5822 or at email@example.com. Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Pharmaceuticals industry, follow our LinkedIn Pharma Showcase Page, or connect with us on: Facebook | LinkedIn | Twitter.
Total Page Views: 4918